← SEC 公告列表 | LMRI SEC 公告 | Lumexa Imaging Holdings, Inc.(LMRI)

重大事件 即時報告 8-K 2026-06-30

Lumexa Imaging 簽訂信貸協議修訂,獲8.23億美元定期貸款及2.5億美元循環信貸

於 SEC 網站開啟原文

AI 繁中摘要

📄 **Lumexa Imaging Holdings 提交8-K報告:簽訂重大信貸協議修訂,涉及約8.23億美元定期貸款及2.5億美元循環信貸** Lumexa Imaging Holdings, Inc.(納斯達克代碼:LMRI)於2026年6月30日提交8-K申報文件,披露其間接全資子公司Lumexa Imaging, Inc.及Lumexa Imaging Outpatient, Inc.與其他貸款方、貸款人及行政代理Barclays Bank PLC簽訂了現有信貸協議的第7號修訂(「經修訂信貸協議」)。 **主要條款一覽** 💰 - **定期貸款**:約8.23億美元(「替代定期貸款」),利率可選擇SOFR加2.50%或Prime Rate加1.50%,2032年12月到期。 - **循環信貸**:2.5億美元(「經修訂循環信貸」),利率同為SOFR加2.50%或Prime Rate加1.50%(若達致特定優先擔保淨槓桿率可調低),2030年12月到期。 - **擔保及抵押**:由公司幾乎所有全資附屬公司擔保,並以幾乎所有資產作抵押(部分例外情況)。 **契約限制** 📝 經修訂信貸協議包含多項限制性契約,限制附屬公司額外借貸、派發股息及其他分派,並設有財務契約:若循環信貸未償還風險超過總額40%(按適用季度報告期末計算),則公司的合併淨槓桿率不得超過7.50:1。未能遵守該等契約可能構成違約事件,即使附屬公司有能力償還債務;貸款人亦擁有慣常的違約補救措施。 **對投資者的潛在影響** 此項融資安排顯著提升了公司的債務規模,但同時提供了約10.73億美元的總流動性(定期貸款加循環信貸),有助支持營運及潛在擴張。然而,較高的槓桿率限制(7.50倍)及嚴格的契約條款,可能限制公司未來的財務靈活性,尤其若收入或現金流出現波動。投資者需關注公司後續季度報告中的槓桿率變化及合規情況。 *此摘要基於公司於2026年6月30日提交的8-K申報文件,僅供參考,不構成投資建議。*
展開英文正文
8-K

 false 0002071288 0002071288 2026-06-30 2026-06-30 
  
  
 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
  
  

 FORM 8-K
  
  

 CURRENT REPORT
 PURSUANT TO SECTION 13 OR 15(d)
 OF THE SECURITIES EXCHANGE ACT OF 1934
 Date of report (Date of earliest event reported): June 30, 2026
  
  

 Lumexa Imaging Holdings, Inc.
 (Exact Name of Registrant as Specified in its Charter)
  
  

  

Delaware
 
001-43010
 
41-2605845

 (State or Other Jurisdiction
 of Incorporation)

 
 (Commission
 File Number)

 
 (IRS Employer
 Identification No.)

  

4200 Six Forks Road
 

Suite 1000
 

Raleigh, North Carolina
 
27609

(Address of Principal Executive Offices)
 
(Zip Code)
 (919) 763-1100
 (Registrant’s telephone number, including area code)
 Not applicable
 (Former Name or Former Address, if Changed Since Last Report)
  
  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  

☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  

☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  

☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:
  

 Title of each class

 
 Trading
 Symbol

 
 Name of each exchange
 on which registered

Common Stock, $0.001 par value per share
 
LMRI
 
The Nasdaq Stock Market LLC
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 Emerging growth company ☒
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  
  
  

 

Item 1.01.
 Entry into a Material Definitive Agreement. 

 On June 30, 2026, Lumexa Imaging, Inc. and Lumexa Imaging Outpatient, Inc. (collectively, the “Borrowers”), each an indirect wholly-owned subsidiary of Lumexa Imaging Holdings, Inc. (the “Company”), the other Loan Parties party thereto, the Lenders party thereto and Barclays Bank PLC, as administrative agent, entered into an amendment to their existing Credit Agreement (as so amended, the “Amended Credit Agreement”). Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the Amended Credit Agreement. 
 The Amended Credit Agreement provides for (i) a secured term loan facility of approximately $823 million (the “Replacement Term Loan”) and (ii) a secured revolving line of credit of $250 million (the “Amended Revolving Credit Facility”). The Replacement Term Loan will bear interest at a rate per annum equal to, at the option of the Borrowers, SOFR plus 2.50% or the Prime Rate plus 1.50%, and will mature in December 2032. The Amended Revolving Credit Facility will bear interest at a rate per annum equal to, at the option of the Borrowers, SOFR plus 2.50% or the Prime Rate plus 1.50% (subject to reduction upon the achievement of certain senior secured net leverage ratios), and will mature in December 2030. The Amended Credit Agreement contains various restrictive covenants that limit the ability of the Company’s subsidiaries to incur additional debt, pay dividends and other distributions, and engage in certain other transactions as specified therein. The Amended Credit Agreement also contains a financial covenant that must be met if outstanding revolving credit exposure exceeds 40% of the aggregate principal amount of the Amended Revolving Credit Facility on the last day of the applicable quarterly reporting period. If the covenant is triggered, the Company’s consolidated net leverage ratio on the last day of the test period shall not exceed 7.50 to 1. Failure to comply with these covenants could constitute an event of default notwithstanding the ability of the Company’s subsidiaries to meet their debt service obligations. The Amended Credit Agreement includes various customary remedies for the Lenders following an event of default. The Amended Credit Agreement is guaranteed by substantially all wholly-owned subsidiaries of the Company and is secured by substantially all of their assets, subject to certain exceptions. 
 The foregoing description of the Amended Credit Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of Amendment No. 7 to the Amended Credit Agreement, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference. 
  

Item 2.03.
 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. 

 The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03. 
  

Item 9.01.
 Financial Statements and Exhibits. 

 (d) Exhibits.
  

Exhibit
No.
  
Description

10.1
  
Amendment No. 7 to Credit Agreement, dated as of June 30, 2026, among Lumexa Imaging, Inc. and Lumexa Imaging Outpatient, Inc., as borrowers, Lumexa Imaging Intermediate Holdings, Inc. and Lumexa Imaging Outpatient Intermediate Holdings, Inc., as holding entities, the other Loan Parties party thereto, the Lenders party thereto and Barclays Bank PLC, as administrative agent. 

104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 SIGNATURES 
 Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
  

 

 
LUMEXA IMAGING HOLDINGS, INC.

Date: June 30, 2026
 

 
By:
 
 /s/ J. Anthony Martin

 

 
Name:
 
J. Anthony Martin

 

 
Title:
 
Chief Financial Officer